Toward Orally Absorbed Prodrugs of the Antibiotic
Aztreonam. Design of Novel Prodrugs of Sulfate Containing Drugs. Part
2

Gordon, Eric M.; Duncton, Matthew A. J.; Wang, Brian J.; Qi, Longwu; Fan, Dazhong; Li, Xianfeng; Ni, Zhi-Jie; Ding, Pingyu; Grygorash, Ruslan; Low, Eddy; Yu, Guijun; Sun, Jiawei

doi:10.1021/acsmedchemlett.9b00534.s001

ml9b00534_si_001.pdf (521.45 kB)

Toward Orally Absorbed Prodrugs of the Antibiotic Aztreonam. Design of Novel Prodrugs of Sulfate Containing Drugs. Part 2

journal contribution

posted on 2020-01-10, 14:39 authored by Eric M. Gordon, Matthew A. J. Duncton, Brian J. Wang, Longwu Qi, Dazhong Fan, Xianfeng Li, Zhi-Jie Ni, Pingyu Ding, Ruslan Grygorash, Eddy Low, Guijun Yu, Jiawei Sun

Aztreonam, first discovered in 1980, is an FDA approved, intravenous, monocyclic beta-lactam antibiotic. Aztreonam is active against Gram-negative bacteria and is still used today. The oral bioavailability of aztreonam in humans is less than 1%. Herein we describe the design and synthesis of potential oral prodrugs of aztreonam.